RxDoctor Payments Data

Robert Stark, MD

Family Medicine · Rockwall, TXNPI 1427035484

Payments from drug & device makers

$9,946in general payments, 2019–2025

Across 512 payments — averaging $19.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Harmony Biosciences LLC$928
  • Abbott$903
  • Amgen$830
  • Pfizer$786
  • AbbVie$579
  • plus $5K from 51 others

What the payments were for

  • Consulting fees$7808%
  • Food & beverage$9,14392%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk61$1,032
Harmony Biosciences LLC2$928
Abbott32$903
Amgen(2 entities)49$830
Pfizer42$786
AbbVie37$579
GSK33$536
AstraZeneca29$533
Lilly USA, LLC29$465
Merck24$321
Bayer15$264
Astellas Pharma US Inc13$264
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$243
Amarin Pharma, Inc.14$204
Biohaven Pharmaceuticals, Inc.6$187
Esperion Therapeutics, Inc.7$151
Antares Pharma, Inc.9$142
Boehringer Ingelheim9$138
Biohaven Pharmaceutical Holding Company Ltd.6$96
Genentech USA, Inc.5$78
Ironshore Pharmaceuticals Inc.5$78
Dexcom, Inc.4$69
Halozyme Inc5$69
Verity Pharmaceuticals Inc.3$64
Corcept Therapeutics2$62
Exact Sciences3$62
Sanofi-aventis U.S. LLC3$58
Johnson & Johnson3$57
Tris Pharma Inc3$54
Dynavax Technologies Corporation3$53
Teva Pharmaceuticals USA, Inc.4$52
Optinose US, Inc.3$49
Novartis2$36
Sanofi Pasteur Inc.2$34
Ironwood Pharmaceuticals, Inc2$34
Axsome Therapeutics, Inc.2$33
Idorsia Pharmaceuticals US Inc2$28
Corium, LLC1$28
Inari Medical, Inc.1$26
Nalpropion Pharmaceuticals LLC2$26
Kowa Pharmaceuticals America, Inc.2$25
Takeda Pharmaceuticals U.S.A., Inc.4$23
ARS Pharmaceuticals Operations, Inc.1$23
Boston Scientific1$22
Neos Therapeutics, LP1$22
Seqirus USA Inc1$21
Scilex Pharmaceuticals Inc.1$19
Upsher-smith Laboratories LLC1$18
Inogen, Inc.1$17
Otsuka America Pharmaceutical, Inc.1$16
Supernus Pharmaceuticals, Inc.1$14
Endo Pharmaceuticals Inc.1$14
Neuronetics, Inc.1$14
Phathom Pharmaceuticals, Inc.1$12
Adlon Therapeutics L.p.1$12
Clarus Therapeutics Inc.1$12
Echosens North America, Inc.2$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,946 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$151,655
Medicare patients
260
Services billed
2,172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$92,522
MounjaroTirzepatide60$88,942
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$40,539
EliquisApixaban22$30,632
FarxigaDapagliflozin Propanediol15$24,801
Tresiba Flextouch U-200Insulin Degludec13$20,802
XareltoRivaroxaban21$19,665
JardianceEmpagliflozin12$9,340
Rosuvastatin Calcium469$5,486
Duloxetine Hcl125$3,528
Azelastine-FluticasoneAzelastine/Fluticasone13$3,074
Celecoxib108$2,884
Valsartan74$2,842
Azelastine Hcl65$2,810
Levothyroxine Sodium237$2,771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,032$92,52248 claims
Lilly USA, LLCMounjaro$465$88,94260 claims
GSKTrelegy Ellipta$536$40,53932 claims
PfizerEliquis$786$30,63222 claims
AstraZenecaFarxiga$533$24,80115 claims
Johnson & JohnsonXarelto$57$19,66521 claims
Boehringer IngelheimJardiance$138$9,34012 claims
AbbVieSynthroid$579$2,08336 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Rockwall

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →